Efflux pump inhibitory activity of biologically synthesized silver nanoparticles against multidrug-resistant

Reyhaneh Behdad1, Minoo Pargol1, Amir Mirzaie2

  • 1Department of Biology, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran.

Insights

Biologically synthesized silver nanoparticles (AgNPs) show efflux pump inhibitory activity against multidrug-resistant (MDR) Acinetobacter baumannii. This suggests AgNPs may combat MDR bacteria by downregulating efflux pump genes.

Area of Science:

  • Nanotechnology
  • Microbiology
  • Biochemistry

Background:

  • Multidrug-resistant (MDR) Acinetobacter baumannii poses a significant clinical challenge.
  • Efflux pumps are a major mechanism contributing to MDR in bacteria.
  • Novel strategies are needed to overcome antibiotic resistance.

Purpose of the Study:

  • To investigate the efflux pump inhibitory activity of biologically synthesized silver nanoparticles (AgNPs).
  • To evaluate the effect of AgNPs on efflux pump gene expression in MDR A. baumannii.

Main Methods:

  • Physicochemical characterization of AgNPs using SEM, TEM, XRD, and FTIR.
  • Identification of efflux pump genes in MDR A. baumannii using PCR.
  • Quantitative real-time PCR to assess gene expression after AgNP treatment.
  • Ethidium bromide (EtBr) synergy assay to confirm efflux pump inhibition.

Main Results:

  • Synthesized AgNPs exhibited spherical nanostructures (mean size 38.89 nm).
  • AgNP treatment significantly downregulated the expression of key efflux pump genes (AdeA, AdeC, AdeS, AdeR, AdeI, AdeJ, AdeK).
  • AgNPs reduced the minimum inhibitory concentration (MIC) of EtBr, indicating efflux pump inhibition.

Conclusions:

  • Biologically synthesized AgNPs possess significant efflux pump inhibitory activity against MDR A. baumannii.
  • This inhibitory activity is a potential mechanism underlying the antibacterial effects of AgNPs.
  • AgNPs represent a promising therapeutic agent to combat MDR bacterial infections.